STOCK TITAN

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Schrödinger (Nasdaq: SDGR), a company revolutionizing drug and materials discovery through physics-based computational methods, has announced the granting of restricted stock units (RSUs) to eight new employees on September 13, 2024. The grants, totaling 7,025 shares of common stock, were approved under the company's 2021 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). These RSUs are designed to vest over four years, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. This move serves as a material inducement for the new hires, aligning their interests with the company's long-term success.

Schrödinger (Nasdaq: SDGR), una società che sta rivoluzionando la scoperta di farmaci e materiali attraverso metodi computazionali basati sulla fisica, ha annunciato l'assegnazione di unità di azioni riservate (RSU) a otto nuovi dipendenti il 13 settembre 2024. I conferimenti, per un totale di 7.025 azioni ordinarie, sono stati approvati nell'ambito del piano di incentivazione azionaria per l'anno 2021 dell'azienda e sono conformi alla Regola di quotazione n. 5635(c)(4) di Nasdaq. Queste RSU sono progettate per maturare in quattro anni, con il 25% che matura dopo il primo anno di servizio continuativo e il restante 75% che matura in rate annuali uguali nei successivi tre anni. Questa mossa rappresenta un incentivo sostanziale per i nuovi assunti, allineando i loro interessi con il successo a lungo termine dell'azienda.

Schrödinger (Nasdaq: SDGR), una empresa que está revolucionando el descubrimiento de fármacos y materiales a través de métodos computacionales basados en la física, ha anunciado la concesión de unidades de acciones restringidas (RSU) a ocho nuevos empleados el 13 de septiembre de 2024. Las concesiones, por un total de 7,025 acciones comunes, fueron aprobadas bajo el Plan de Incentivos de Equidad de Inducción de la compañía de 2021 y cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq. Estas RSU están diseñadas para adquirirse en cuatro años, con el 25% que se adquiere después del primer año de servicio continuo y el 75% restante que se adquiere en cuotas anuales iguales durante los tres años siguientes. Este movimiento sirve como un incentivo material para los nuevos empleados, alineando sus intereses con el éxito a largo plazo de la empresa.

슈뢰딩거(Schrödinger) (나스닥: SDGR)는 물리 기반의 계산 방법을 통해 의약품 및 자재 발견을 혁신하는 회사로, 2024년 9월 13일에 8명의 신규 직원에게 제한 주식 단위(RSU)를 부여한다고 발표했습니다. 이 부여는 총 7,025주의 보통주로, 회사의 2021년 유인 자본 인센티브 계획에 따라 승인되었으며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다. 이러한 RSU는 4년 동안 성과가 발생하도록 설계되어 있으며, 첫 해의 지속적인 서비스 후 25%가 성과하고 나머지 75%는 다음 3년 동안 동일한 연간 할부로 성과됩니다. 이 조치는 신규 채용자에게 실질적인 유인을 제공하며, 회사의 장기 성공과 그들의 이익을 일치시킵니다.

Schrödinger (Nasdaq: SDGR), une entreprise qui révolutionne la découverte de médicaments et de matériaux grâce à des méthodes computationnelles basées sur la physique, a annoncé l'attribution d'unités d'actions restreintes (RSU) à huit nouveaux employés le 13 septembre 2024. Les attributions, totalisant 7 025 actions ordinaires, ont été approuvées dans le cadre du Plan d'Incinération de Capitaux de 2021 de l'entreprise et sont conformes à la règle de cotation 5635(c)(4) de Nasdaq. Ces RSU sont conçues pour s'acquérir sur quatre ans, avec 25 % s'acquérant après la première année de service continu et les 75 % restants s'acquérant en versements annuels égaux au cours des trois années suivantes. Cette initiative constitue une incitation matérielle pour les nouvelles recrues, alignant leurs intérêts sur le succès à long terme de l'entreprise.

Schrödinger (Nasdaq: SDGR), ein Unternehmen, das die Entdeckung von Medikamenten und Materialien durch physikbasierte Berechnungsmethoden revolutioniert, hat am 13. September 2024 die Gewährung von eingeschränkten Aktieneinheiten (RSUs) an acht neue Mitarbeiter bekannt gegeben. Die Zuteilungen, die insgesamt 7.025 Aktien beinhalten, wurden im Rahmen des Akt incentive-Programms 2021 des Unternehmens genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Diese RSUs sind darauf ausgelegt, über vier Jahre zu vesten, wobei 25% nach dem ersten Jahr ununterbrochener Dienstzeit und die verbleibenden 75% in gleichmäßigen jährlichen Raten über die folgenden drei Jahre vesten. Diese Maßnahme dient als wesentlicher Anreiz für die neuen Mitarbeiter und bringt ihre Interessen mit dem langfristigen Erfolg des Unternehmens in Einklang.

Positive
  • Attraction of new talent with equity incentives
  • Alignment of employee interests with company's long-term performance
Negative
  • Potential dilution of existing shareholders' equity

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on September 13, 2024, the company granted restricted stock units (RSUs) with respect to 7,025 shares of the company’s common stock to eight newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Investor contact:

Allie Nicodemo

allie.nicodemo@schrodinger.com

Source: Schrödinger

FAQ

How many RSUs did Schrödinger (SDGR) grant to new employees on September 13, 2024?

Schrödinger (SDGR) granted a total of 7,025 restricted stock units (RSUs) to eight newly hired employees on September 13, 2024.

What is the vesting schedule for the RSUs granted by Schrödinger (SDGR)?

The RSUs vest over four years, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years.

Under which plan were the RSUs granted by Schrödinger (SDGR)?

The RSUs were granted under Schrödinger's 2021 Inducement Equity Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the purpose of Schrödinger (SDGR) granting these RSUs?

The RSUs were granted as a material inducement to attract new employees and align their interests with the company's long-term success.

Schrodinger, Inc.

NASDAQ:SDGR

SDGR Rankings

SDGR Latest News

SDGR Stock Data

1.51B
62.15M
2.39%
96.24%
12.22%
Health Information Services
Pharmaceutical Preparations
Link
United States of America
NEW YORK